Aditxt, Inc. is a biotechnology firm dedicated to advancing immune system health through innovative mapping and reprogramming techniques. The company's developments include AditxtScore, a platform designed to empower individuals by providing insights into their immune profiles for better management and informed awareness of immune system attacks or dysfunctions. Aditxt also pioneers Apoptotic DNA Immunotherapy, a nucleic acid-based solution that emulates the body's inherent mechanisms for developing self-tolerance to its own tissues.
| Date | Est. | Actual | |
|---|---|---|---|
| May 20, 2026 | -$2,245,536,000.00 | -$2.06 | Beat |
| Feb 25, 2026 | -$6,443,712.00 | -$1.48 | Beat |
| Nov 17, 2025 | -$6,687,792.00 | -$158.16 | Beat |
| Aug 14, 2025 | -$6,565,752.00 | -$847.67 | Beat |
| May 15, 2025 | -$8,127,864.00 | -$1,995.09 | Beat |
| Apr 14, 2025 | -$72,760,248.00 | -$10,910,376.00 | Beat |